Bio-Path Holdings, Inc. (NASDAQ:BPTH) Sees Large Growth in Short Interest

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 250,000 shares, a growth of 189.4% from the December 15th total of 86,400 shares. Approximately 5.8% of the company’s shares are sold short. Based on an average daily trading volume, of 3,070,000 shares, the short-interest ratio is presently 0.1 days.

Institutional Investors Weigh In On Bio-Path

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC purchased a new position in Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path as of its most recent SEC filing. Institutional investors own 5.74% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on Bio-Path in a research note on Saturday, January 11th. They set a “sell” rating on the stock.

Bio-Path Price Performance

BPTH opened at $0.85 on Thursday. Bio-Path has a 52-week low of $0.59 and a 52-week high of $10.78. The stock’s 50 day moving average price is $0.90 and its 200-day moving average price is $1.15.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.